---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-053099"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:25:34.937555+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PDS Biotech Q3 net loss $10.8M; highlights 74% 2-year OS in VERSATILE-002 trial

## Summary
- Net loss of $10.8M ($0.35/share) vs $7.4M loss in Q3 2022; R&D expenses rose to $6.4M from $4.4M.
- Cash $54.3M at Sept 30, expected to fund operations into Q3 2024; VERSATILE-003 Phase 3 initiation planned Q1 2024.
- VERSATILE-002 interim: 24-month overall survival rate of 74% in ICI-naïve HPV+ head & neck cancer patients.
- NCI triple combo: 75% of ICI-naïve HPV+ cancer patients alive at 36 months; median OS not reached.
- PDS01ADC+docetaxel: PSA decreased in all 18 prostate cancer patients; 61% had ≥60% PSA decline.

## SEC filing metadata
- accession: 0001140361-23-053099
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036123053099/0001140361-23-053099-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036123053099/ef20014629_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-053099
- JSON: https://secwatch.observer/filing/0001140361-23-053099.json
- Plain text: https://secwatch.observer/filing/0001140361-23-053099.txt

## Key facts
- Earnings Releases
  PDS Biotechnology Corp reported financial results for the quarter ended September 30, 2023.
  - Period: the quarter ended September 30, 2023
  - Result: reported results
  source text: On November 14, 2023, PDS Biotechnology Corporation (the “Company”) issued a press release announcing its financial results as of and for the three and nine months ended September 30, 2023 and provided an update on the business of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472091/000114036123053099/0001140361-23-053099-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.